Sciensus

Sciensus: clinical homecare and medicine delivery across the UK and Europe

Sciensus describes itself as the UK's leading provider of complex clinical care at home. The organisation states that for more than 30 years it has worked with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions. Its own figures put the scale of that activity at more than 300,000 patients a year across over 180 NHS trusts.

Outside the UK, the company positions itself as a partner for pharmaceutical and biotech companies seeking to reach patients across Europe, taking on the regulatory, logistics and patient-support complexity involved in launching medicines in several markets at once.

Services spanning dispensing, nursing and market access

The service catalogue is organised around several blocks. Under end-to-end dispense and delivery, Sciensus lists supply chain management, pharmaceutical storage and distribution, dispense and delivery, purchasing and cash collection, and packaging and labelling, described as safe, compliant pan-European logistics from import and title through to last-mile delivery and order-to-cash.

Treatment delivery and ongoing engagement covers specialist nurses and digital tools supporting patients at home, with the stated aim of improving adherence, persistence and outcomes. This block includes digital solutions, patient support programmes, nursing and clinical services, and clinical homecare.

Market access support addresses regulatory, pricing and reimbursement systems in Europe, with early access programmes, regulatory approval consulting and pricing reimbursement support. A further area, clinical study support and real-world evidence, lists real-world data, early access programmes, patient support programmes, pharmacovigilance, decentralised clinical trial services, post-authorisation safety studies (PASS) and non-interventional studies.

Cancer care and compounding

Sciensus reports providing at-home cancer care for 4,000 patients each year, delivering more than 400 SACT regimens through specialist nurses and a dedicated compounding unit. Cancer services are grouped into cancer care at home and aseptic compounding.

For health systems, the company presents homecare services, digital tools and other approaches as a way to relieve capacity pressures on the NHS and other systems. The listed offerings in this area include blood monitoring services, e-prescription services, non-medical prescribing, clinical screening services and switching services.

Therapeutic areas and reported volumes

Sciensus concentrates on three therapeutic groups: cancer, chronic conditions, and rare and specialty diseases.

• Cancer: at-home care for 4,000 patients a year, with over 400 SACT regimens delivered through specialist nurses and a dedicated compounding unit.
• Chronic conditions: support for 300,000 patients a year with digitally enabled, clinician-led care, which the company says improves adherence by over 10% and generates real-world insights across 70 therapy areas.
• Rare and specialty diseases: access to rare and specialty medicines across Europe, with 300,000 units supplied annually to more than 4,000 hospitals and pharmacies and, according to the company, $400m of orphan drugs traded each year.

Digital model and data

The company describes a model that combines human care with digital tools, built on what it calls a proprietary integrated intelligence engine. According to its presentation, these solutions are intended to improve patient engagement, connect clinicians to the patient journey, optimise operations for health systems and capture more accurate and timely real-world data. Artificial intelligence is applied to that data for predictive analytics and outcome tracking, with the stated goal of informing decisions and enabling proactive treatment modifications.

Sciensus also cites 30 years of experience and insights drawn from more than 70 million interactions as the basis of its clinical expertise.

Who it works with

The organisation frames its partnerships around three groups. For biopharma, it offers infrastructure, expertise and digital capability for launching therapies, scaling market access across Europe and generating real-world evidence. For health systems, it presents an end-to-end service intended to create capacity through medication dispensing, digitally enabled clinician-led care and patient support programmes. For CROs and CCOs, it proposes partnerships to expand capabilities, enter new geographies and add capacity across the drug development lifecycle, from non-interventional trials to launch planning, early access programmes and pan-European distribution.

The site also maintains a separate patient hub with support, guidance and resources, and lists partnerships with the NHS, healthcare professionals and biopharma among its areas of activity.